Evidence map›Paper›PMID 38776216›Full record

ArticleEpilepsia2024

How accurate do self-reported seizures need to be for effective medication management in epilepsy?

Daniel Goldenholz, Benjamin H Brinkmann, M Brandon Westover

Abstract read
In one paragraph

Article in Epilepsia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel GoldenholzDepartment of Neurology, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8370-2758
Benjamin H BrinkmannDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-2392-8608
M Brandon WestoverDepartment of Neurology, Harvard Medical School, Boston, Massachusetts, USA.

Funding

Data-Driven Sleep Biomarkers of Brain Health, Heart Health, and MortalityR01HL161253 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CLIFFORD, GARI DAVID, MIGNOT, EMMANUEL J · 2022 to 2025
$8.3M
Comparative Safety of Seizure Prophylaxis within the Medicare ProgramR01AG073410 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Lidia Maria Veras Rocha de Moura · 2021 to 2026
$4.1M
Low Neurophysiologic Resistance to Anesthetics as a Marker of Preclinical/Prodromal Alzheimer's Disease and Neurovascular Pathology, Delirium risk and InattentionR01AG073598 · NIA · STANFORD UNIVERSITY · PI Miles Berger · 2022 to 2026
$3.8M
Integrative Motor Activity Biomarker for the Risk of Alzheimer's RiskRF1AG064312 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI HU, KUN · 2019 to 2019
$3.6M
Multimodal Network Connectivity Architecture (MOCA) of the Brain and its Role in the Recovery of Consciousness in Comatose Cardiac Arrest PatientsR01NS102574 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GREER, DAVID MATTHEW, WU, ONA · 2018 to 2022
$3.4M
Investigation of Sleep in the Intensive Care Unit (ICU-SLEEP)R01NS102190 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WESTOVER, MICHAEL BRANDON · 2018 to 2022
$3.2M
Prospective Validation of Neurophysiologic Outcome Prediction in Acute Brain InjuryR01NS126282 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Aaron F Struck, Michael Brandon Westover · 2023 to 2026
$2.9M
Big Data and Deep Learning for the Interictal-Ictal-Injury ContiuumR01NS107291 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WESTOVER, MICHAEL BRANDON · 2018 to 2022
$2.8M
Establishing a Brain Health Index from the Sleep ElectroencephalogramRF1NS120947 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CASH, SYDNEY S, THOMAS, ROBERT JOSEPH · 2021 to 2021
$2.4M
Optimizing Pharmacotherapy with Noninvasive Wearable Sensors and Subscalp EEGUH3NS123066 · NINDS · MAYO CLINIC ROCHESTER · PI Benjamin H Brinkmann, Gregory A Worrell · 2025 to 2026
$1.4M
Optimizing Pharmacotherapy with Noninvasive Wearable Sensors and Subscalp EEGUG3NS123066 · NINDS · MAYO CLINIC ROCHESTER · PI BRINKMANN, BENJAMIN H, WORRELL, GREGORY A · 2022 to 2024
$1.2M
Non-Invasive Seizure Forecasting System Using E-Diaries, Internal and External FactorsK23NS124656 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Daniel M Goldenholz · 2022 to 2026
$954k
Epilepsy FoundationNational Science Foundation 2014431NHLBI NIH HHS R01 HL161253NIA NIH HHS R01 AG073410NIA NIH HHS R01 AG073598NIA NIH HHS RF1 AG064312NINDS NIH HHS K23 NS124656NINDS NIH HHS K23NS124656NINDS NIH HHS R01AG073410NINDS NIH HHS R01AG073598NINDS NIH HHS R01HL161253NINDS NIH HHS R01 NS102190NINDS NIH HHS R01NS102190NINDS NIH HHS R01 NS102574NINDS NIH HHS R01NS102574NINDS NIH HHS R01 NS107291NINDS NIH HHS R01NS107291NINDS NIH HHS R01 NS126282NINDS NIH HHS R01NS126282NINDS NIH HHS RF1AG064312NINDS NIH HHS RF1 NS120947NINDS NIH HHS RF1NS120947NINDS NIH HHS UG3 NS123066NINDS NIH HHS UG3NS123066NINDS NIH HHS UH3 NS123066
6 · The paper itself

Abstract

Studies suggest that self-reported seizure diaries suffer from 50% under-reporting on average. It is unknown to what extent this impacts medication management. This study used simulation to predict the seizure outcomes of a large heterogeneous clinic population treated with a standardized algorithm based on self-reported seizures. Using CHOCOLATES, a state-of-the-art realistic seizure diary simulator, 100 000 patients were simulated over 10 years. A standard algorithm for medication management was employed at 3 month intervals for all patients. The impact on true seizure rates, expected seizure rates, and time-to-steady-dose were computed for self-reporting sensitivities 0%-100%. Time-to-steady-dose and medication use mostly did not depend on sensitivity. True seizure rate decreased minimally with increasing self-reporting in a non-linear fashion, with the largest decreases at low sensitivity rates (0%-10%). This study suggests that an extremely wide range of sensitivity will have similar seizure outcomes when patients are clinically treated using an algorithm similar to the one presented. Conversely, patients with sensitivity ≤10% would be expected to benefit (via lower seizure rates) from objective devices that provide even small improvements in seizure sensitivity.

Indexed as

AlgorithmsAnticonvulsantsEpilepsySeizuresSelf ReportAdultComputer SimulationFemaleHumansMaleTreatment OutcomeAnticonvulsantsclinicalpatient‐reported outcomesseizuressimulation

Identifiers

PMID38776216
PMCPMC11251847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.